What Has Been the Progress and Growth of the Abrysvo Or Arexvy Market in Recent Years?
The abrysvo or arexvy market has seen considerable growth due to a variety of factors.
• In recent times, the abrysvo or arexvy market has experienced a XX (HCAGR). The market is projected to expand from $XX million in 2024 to $XX million in 2025, demonstrating a compound annual growth rate (CAGR) of XX%.
The increase during the historical phase can be credited to factors such as an increasing elderly population, commencement of immunization schemes, heightened consciousness about respiratory diseases, governmental health interventions, and epidemics of seasonal respiratory diseases.
What Can Be Expected from the Abrysvo Or Arexvy Market in the Coming Years?
The abrysvo or arexvy market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of abrysvo or arexvy is predicted to increase at a future compound annual growth rate (FCAGR) of XX% in the coming years. This increase is estimated to result in a market value of $XX million by 2029, demonstrating a compound annual growth rate (CAGR) of XX%.
This expected growth during the forecast period is due to factors including a rising elderly population, increased access to vaccines and their international delivery, an growing emphasis on preventative healthcare, an increased occurrence of respiratory infections, and enhanced healthcare policies and schemes. Key trends during this period comprise developments in vaccine technology, personalized healthcare, the incorporation of wearable health technology, innovative vaccine delivery methods, refrigerated transportation, and smart packaging.
What Are the Critical Driver Fuelling The Abrysvo Or Arexvy Market's Growth?
The escalating incidence of respiratory syncytial virus (RSV) infections is anticipated to fuel the expansion of the abrysvo or arexvy market in the future. RSV infections, caused by the respiratory syncytial virus, predominantly affect the respiratory tract, leading to mild cold-like symptoms in most people, but potentially severe illness in infants, the elderly, and those with compromised immune systems. Factors contributing to the escalating incidence of RSV infections include the highly contagious nature of the virus, the occurrence of seasonal outbreaks, the absence of widespread immunity, and a higher vulnerability in at-risk groups such as infants and seniors. Abrysvo aims to counteract the incidence of RSV infections by providing specially designed vaccines that shield high-risk groups, including older adults and infants, from severe illnesses related to the respiratory syncytial virus. For instance, data from the US-based health protection agency, the Centers for Disease Control and Prevention, showed that during the 2024-25 season, hospitalization rates related to RSV stood at 3.2 for every 100,000 individuals. Consequently, the high incidence of RSV infections propels the expansion of the abrysvo or arexvy market.
How Is The Abrysvo Or Arexvy Market segmented?
The abrysvo or arexvy market covered in this report is segmented –
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection
2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)
3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults
Pre-Book The Abrysvo Or Arexvy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Abrysvo Or Arexvy Market?
The predominant trend in the abrysvo or arexvy market revolves around increasing age indications to widen the usage of the vaccine across various age demographics. This approach aims to enhance public health security and expand market penetration. The RSVpreF vaccine, or bivalent RSV prefusion F, is specifically engineered to offer resistance against respiratory syncytial virus (RSV). It targets both RSV-A and RSV-B variants. For example, in October 2024, Pfizer Inc., a pharmaceutical corporation from the US, was granted FDA approval for ABRYSVO (RSV Vaccine), an RSVpreF vaccine, to prevent lower respiratory tract disease among adults between 18 and 59 years of age who are at increased risk; thereby extending its usage to a wider adult population. This continues to be the only sanctioned RSV vaccine for expectant mothers in their 32nd to 36th weeks of pregnancy, offering protection to newborns until they reach six months old.
Who Are the Key Players In The Abrysvo Or Arexvy Market?
Major companies operating in the abrysvo or arexvy market include:
• Pfizer Inc.
• GlaxoSmithKline plc (GSK)
What Is The Most Dominant Region In The Abrysvo Or Arexvy Market?
North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
